Literature DB >> 33990097

CDH1 germline mutations in families with hereditary lobular breast cancer.

Antonia Girardi1, Francesca Magnoni1, Elisa Vicini1, Andriana Kouloura2, Carlo La Vecchia3, Paolo Veronesi1,4, Giovanni Corso1,4.   

Abstract

Pathogenic CDH1 germline mutations are associated with lobular breast cancer in the so-called hereditary lobular breast cancer (HLBC) syndrome, without apparent correlation with the classic hereditary diffuse gastric cancer (HDGC). Recent international guidelines recommend CDH1 screening also in absence of diffuse gastric cancer (DGC) history. Genomic characteristics underlying gastric and breast tumorigenesis in this varied population of patients is still unclear. In this review we revised all CDH1 germline mutations described in literature associated with lobular breast cancer (LBC). We distinguish two subgroups of CDH1 mutant carriers: (a) 'mixed' HDGC syndrome, showing both DGC plus LBC and (b) HLBC, in which DGC is absent and the LBC phenotype is predominant. A higher frequency of CDH1 mutations was identified in the HLBC syndrome with an early age at LBC diagnosis; it is possible that LBCs with CDH1 germline mutations are an independent inherited syndrome. This evidence allows us to gain biological insight into the pathophysiological mechanisms responsible for the different phenotypes of the disease and potentially tailor the prophylactic and screening procedures.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 33990097     DOI: 10.1097/CEJ.0000000000000688

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  2 in total

1.  CDH1 mutations recurrence and global clustering in genetically tested families with hereditary diffuse gastric cancer syndrome: results from a systematic study.

Authors:  Giovanni Corso; Valentina Tagliaferri; Giulia Massari; Antonio Cioffi; Elisabetta Maria Cristina Rossi; Paolo Veronesi; Francesca Magnoni
Journal:  Fam Cancer       Date:  2022-07-27       Impact factor: 2.446

Review 2.  Pleiotropic cancer manifestations of germline CDH1 mutations: Risks and management.

Authors:  Giovanni Corso
Journal:  J Surg Oncol       Date:  2022-03-12       Impact factor: 2.885

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.